Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | IGF1R | P08069 | 5/20 | 0.38 |
| ▸ | TNK2 | Q07912 | 12/20 | 0.37 |
| ▸ | BTK | Q06187 | 2/20 | 0.36 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.35 |
| ▸ | ABL1 | P00519 | 1/20 | 0.35 |
| ▸ | EGFR | P00533 | 1/20 | 0.35 |
| ▸ | RAF1 | P04049 | 1/20 | 0.35 |
| ▸ | INSR | P06213 | 1/20 | 0.35 |
| ▸ | SRC | P12931 | 1/20 | 0.35 |
| ▸ | KDR | P35968 | 1/20 | 0.35 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2321328 | 1.00 | CNR2 (0.39) | CNR2IGF1RTNK2BTKPDPK1 | |
| SCHEMBL2326851 | 0.84 | TNK2 (0.37) | CNR2IGF1RTNK2 | |
| SCHEMBL2322788 | 0.83 | IDO1 (0.39) | CNR2TNK2BTK | |
| SCHEMBL2322796 | 0.83 | IDO1 (0.39) | CNR2TNK2BTK | |
| SCHEMBL2327527 | 0.82 | CNR2 (0.41) | CNR2IGF1RTNK2 | |
| SCHEMBL2327535 | 0.82 | CNR2 (0.41) | CNR2IGF1RTNK2 | |
| SCHEMBL2321330 | 0.77 | TNK2 (0.42) | IGF1RTNK2PDPK1ABL1EGFR | |
| SCHEMBL2327642 | 0.76 | CNR2 (0.40) | CNR2IGF1R | |
| SCHEMBL2327637 | 0.76 | CNR2 (0.40) | CNR2IGF1R | |
| SCHEMBL14118213 | 0.76 | IGF1R (0.45) | IGF1RTNK2BTKPDPK1ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8658794-B2 | 8-methyl-1-phenyl-imidazol[1,5-a]pyrazine compounds as Lck inhibitors and uses thereof | MERCK SHARP & DOHME B.V. (NL) | 2014-02-25 | — | — | US | disclosed |
| US-20120309966-A1 | 8-METHYL-1-PHENYL-IMIDAZOL[1,5-A]PYRAZINE COMPOUNDS | N.V. ORGANON (NL) | 2012-12-06 | — | — | US | disclosed |
| WO-2011095556-A1 | 8-METHYL-1-PHENYL-IMIDAZOL[1,5-A]PYRAZINE COMPOUNDS | N.V. ORGANON (NL) | 2011-08-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120309966-A1 | 8-METHYL-1-PHENYL-IMIDAZOL[1,5-A]PYRAZINE COMPOUNDS | LCK, ZAP70, FYN | CNR2 2049/4885IGF1R 627/4885TNK2 142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.